0000000000786552

AUTHOR

Mg Alpigiani

showing 3 related works from this author

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

2016

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…

MaleBiologic therapieBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyArthritisJuvenilePediatricsInflammatory bowel diseaseEtanerceptEtanerceptTNF inhibitorsSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineQuality of lifeRetrospective StudieImmunology and AllergyPediatric rheumatology030212 general & internal medicineChildBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyDrug SubstitutionBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyAntirheumatic AgentPerinatology and Child Health3. Good healthTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAntirheumatic AgentsFemaleResearch ArticleHumanmedicine.drugBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcomemedicine.medical_specialtyAdolescent03 medical and health sciencesJuvenile idiopathic arthritiRheumatologyInternal medicineBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitorsmedicineHumansPediatrics Perinatology and Child HealthAdverse effectPreschoolRetrospective StudiesCross-Sectional Studie030203 arthritis & rheumatologybusiness.industryArthritisRetrospective cohort studyJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileRheumatologyDiscontinuationPatient Outcome AssessmentBiologic therapiesCross-Sectional StudiesMethotrexatePediatrics Perinatology and Child HealthPhysical therapybusinessTNF inhibitor
researchProduct

EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arte…

2010

EULAR/PRINTO/PRES Objectives To validate the previously proposed classification criteria for Henoch-Schonlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) and c-Takayasu arteritis (c-TA).Methods Step 1: retrospective/prospective webdata collection for children with HSP, c-PAN, c-WG and c-TA with age at diagnosis <= 18 years. Step 2: blinded classification by consensus panel of a representative sample of 280 cases. Step 3: statistical (sensitivity, specificity, area under the curve and.-agreement) and nominal group technique consensus evaluations.Results 827 patients with HSP, 150 with c-PAN, 60 with c-WG, 87 with c-TA and 52 with c-other were compar…

Genetics and Molecular Biology (all)myalgiaVasculitismedicine.medical_specialtyHenoch-Schonlein purpuraAdolescentIgA VasculitisClassification criteriaInternational CooperationImmunologychildhood polyarteritis nodosaBiochemistryGeneral Biochemistry Genetics and Molecular BiologyRheumatologyhemic and lymphatic diseasesTerminology as TopicSchoenlein-HenochmedicineHumansImmunology and Allergycardiovascular diseasesArteritisChildPurpurac-Wegener granulomatosisAdolescent; Child; Epidemiologic Methods; Granulomatosis with Polyangiitis; Humans; International Cooperation; Polyarteritis Nodosa; Purpura Schoenlein-Henoch; Takayasu Arteritis; Terminology as Topic; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all); Immunology and Allergycriteria; children; Henoch-Schönlein purpura; childhood polyarteritis nodosa; Wegener granulomatosis; Takayasu arteritis; EULAR; PRINTO; PRESPolyarteritis nodosabusiness.industryGranulomatosis with Polyangiitismedicine.diseaseTakayasu ArteritisDermatologyPolyarteritis NodosaSurgeryHenoch-Schönlein purpuraIgA vasculitisSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAmedicine.symptomEpidemiologic MethodsGranulomatosis with polyangiitisVasculitisbusinessRheumatismc-Takayasu arteriti
researchProduct

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients

2014

The advent of biologic medications has considerably increased the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients.

juvenile idiopathic arthritis etanerceptmedicine.medical_specialtyPediatricsbusiness.industryAlternative medicineArthritismedicine.diseaseRheumatologyEtanerceptDisease courseSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicinePoster PresentationPediatrics Perinatology and Child HealthPhysical therapymedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child Healthbusinessmedicine.drug
researchProduct